By: IPP Bureau
Last updated : April 27, 2026 6:52 am
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Indian Immunologicals Limited (IIL) has reported its highest-ever turnover of Rs 1,586 crore for FY2025–26, marking a significant milestone in the company’s growth journey and reinforcing its expanding role in the One Health ecosystem.
The occasion was commemorated in the presence of G. V. Prasad, Co-Chairman and Managing Director of Dr. Reddy's Laboratories, who joined the leadership team and employees to celebrate the achievement.
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%.
Dr K. Anand Kumar, Managing Director, IIL emphasised that the company's ability to balance profitability with social impact has earned it deep trust among governments, healthcare practitioners, patients, and farmers.
“The success is a result of long hours in R&D labs, precision on production floors, tireless efforts by our sales teams, and seamless coordination across functions,” he said, urging employees to continue pushing scientific boundaries while ensuring affordability, quality, and responsible manufacturing.
Speaking at the event, G.V. Prasad drew parallels between IIL and Dr. Reddy’s Laboratories, noting that both organisations are driven by a shared purpose of improving health outcomes.
Prasad commended IIL’s contribution to the One Health approach and its ability to deliver life-saving vaccines at affordable prices through operational efficiency and frugal innovation. “I congratulate the entire team at IIL for serving the nation and wish it continued success,” he said.